About

Clair Brooks, PhD, is an Applications Specialist for Copley Scientific. Providing in-depth application support to those working with orally inhaled and nasal drug products and other pharmaceutical dosage forms, including tablets and capsules, Dr Brooks helps scientists to ensure regulatory compliance during R&D and quality control assessments.

As an accomplished life sciences professional with extensive experience supporting the start-up and operation of heavily regulated testing labs across both industry and academia, Dr Brooks offers support on how best to apply Copley products and services to support pharmaceutical development and manufacture to help maximise return on investment. She also leads Copley’s comprehensive user-training programme, run on-site and at Copley HQ.

Contributions

PULMONARY

DEVELOPING ROBUST ORALLY INHALED PRODUCTS TO ACHIEVE BETTER PATIENT OUTCOMES

Clair Brooks looks at some of the in-use issues and patient effects that good design of devices for orally inhaled drug products can address within the context of regulatory requirements for the demonstration of robustness.

More contributions

PULMONARY

BETTER IN VIVO PREDICTION FROM OINDP TESTING: A GOAL WORTH PURSUING?

Matthew Fenn and Clair Brooks, consider the motivation for adopting more clinically representative test set-ups in orally inhaled and nasal drug product development and, more specifically, for the demonstration of bioequivalence, as well as the practicalities of doing so and the tools available to support such efforts.

PULMONARY

PERFECT TIMING FOR THE AUTOMATION OF OINDP TESTING

Adam Smith and Clair Brooks take a look at the benefits of automation, focusing on the actuation of metered dose inhalers and multidose nasal sprays/aerosols.